Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding Aligos Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 71 | 76 | +5 |
| Shares | 32.9M | 31.8M | −1.09M (−3.3%) |
| Value | $390.4M | $68.4M | −$322.0M (−82.5%) |
New holders (20)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Adage Capital Partners GP, L.L.C. | 1,473,278 | $3.17M | 0.01% |
| IndexIQ Advisors LLC | 192,976 | $415.0K | 0.01% |
| Acadian Asset Management LLC | 175,721 | $377.0K | 0.00% |
| XTX Topco Ltd | 43,936 | $94.0K | 0.04% |
| Mirabella Financial Services LLP | 40,900 | $88.0K | 0.01% |
| Occudo Quantitative Strategies LP | 35,575 | $76.0K | 0.01% |
| Prelude Capital Management, LLC | 27,100 | $58.0K | 0.00% |
| PDT Partners, LLC | 26,694 | $57.0K | 0.00% |
| Schonfeld Strategic Advisors LLC | 26,500 | $57.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 20,770 | $45.0K | 0.00% |
| Denali Advisors LLC | 16,000 | $34.0K | 0.01% |
| ExodusPoint Capital Management, LP | 11,700 | $25.0K | 0.00% |
| Silverarc Capital Management, LLC | 10,659 | $23.0K | 0.01% |
| Barclays PLC | 7,954 | $16.0K | 0.00% |
| FMR LLC | 5,447 | $12.0K | 0.00% |
| Amalgamated Bank | 3,439 | $7.00K | 0.00% |
| Amalgamated Financial Corp. | 3,439 | $7.00K | 0.00% |
| Nisa Investment Advisors, LLC | 2,480 | $5.00K | 0.00% |
| Point72 Hong Kong Ltd | 1,326 | $3.00K | 0.00% |
| Simplex Trading, LLC | 1,294 | $2.00K | 0.00% |
Sold out (15)
Institutions that held Aligos Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Logos Global Management LP | 3,112,785 | $36.9M |
| Cormorant Asset Management, LP | 521,257 | $6.19M |
| Sofinnova Investments, Inc. | 127,791 | $1.52M |
| Millennium Management LLC | 23,133 | $275.0K |
| Algert Global LLC | 22,896 | $272.0K |
| Sectoral Asset Management Inc | 16,908 | $201.0K |
| Gyon Technologies Capital Management, LP | 15,557 | $185.0K |
| Manufacturers Life Insurance Company, The | 12,795 | $152.0K |
| ProShare Advisors LLC | 10,177 | $121.0K |
| MetLife Investment Management | 8,308 | $98.6K |
| UBS Group AG | 7,561 | $90.0K |
| Ensign Peak Advisors, Inc | 7,320 | $87.0K |
| Metropolitan Life Insurance Co | 6,507 | $77.2K |
| Captrust Financial Advisors | 51 | $1.00K |
| State of Wyoming | 111 | $1.00K |